Schaeffer DF, Méndez-Sánchez N

Idioma: Ingles.
Referencias bibliográficas: 6
Paginas: 374-375
Archivo PDF: 27.41 Kb.

FRAGMENTO

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Bruix J, Sherman M. Practice Guidelines Committee, AASLD. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.

2. Iannaccone R, Laghi A, Catalano C, et al. Hepatocellular carcinoma: role of unenhanced and delayed phase multidetector row helical CT in patients with cirrhosis. Radiology 2005; 234: 460-7.

3. Forner A, Vilana R, Ayuso C, Bianchi L, et al. Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. Hepatology 2008; 47: 97-104.

4. Di Tommaso L, Franchi G, Park YN et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in heaptocellular nodules in cirrhosis. Hepatology 2007; 45: 725-34.

5. Di Tommaso L, Destro A, Seok JY, et al. The application of the markers (HSP70, PPC3 and GS) in liver biopsies is useful for the detection of hepatocellular carcinoma. J Hepatol 2009; 50: 746-54.

6. Seimiya M, Tomonaga T, Matsushita K, Sunaga M, et al. Identification of novel immunohistochemical tumor markers for primary hepatocellular carcinoma; clathrin heavy chain and formi-minotransferase cyclodeaminase. Hepatology 2008; 48: 519-30.